A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 3, 2005, Pages 363-372

  Kuru, Bekir ^a,b   Camlibel, M ^a   Dinc, S ^a   Gulcelik, M A ^a   Atalay, C ^a   Alagol, H ^a  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Adjuvant chemotherapy; Breast carcinoma; CMF; FAC

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FILGRISTAM; FLUOROURACIL; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEBRILE NEUTROPENIA; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; METHOTREXATE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 26244451260     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Early Breast Cancer Trialists' Collaborative Group.: an overview of the randomized trials. Lancet 355:1757-1770, 1998.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930-942, 1998.
3. Lohrisch C., Piccard M.J.: Standard medical treatment for early breast cancer. Eur. J. Cancer 37 supp. 7:845-58, 2002.
4. Hartman A.R., Fleming G.F., Dillon J.J.: Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with oestrogen receptor-positive node-positive breast cancer. Clin. Breast Cancer 2:138-143, 2001.
5. Bonadonna G., Brusamolino E., Valagussa P., Veronesi U.: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294:405-410, 1976.
6. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C.: Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N. Engl. J. Med. 332:901-906, 1995.
7. Martin M., Villar A., Sole-Calvo A., et al.: Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1,21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant therapy for operable breast cancer: a study by the GEICAM group. Ann. Oncol. 14:833-842, 2003.
8. Hutchins L., Green S., Ravdin P., et al.: CMF versus CAF with and without tamoxifen in high risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup trial INT 0102. Proc. Am. Soc. Clin. Oncol. 17:1a, 1998.
9. Coombes R.C., Bliss J.M., Wils J., et al.: Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil versus adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J. Clin. Oncol. 14:35-45, 1996.
10. Levine M.N., Bramwell V.H., Pritchard K.I., et al.: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Institute of Canadian Cancer Trials Group. J. Clin. Oncol. 16:3916-3917, 1998.
11. Mouridsen H.T., Andersen J., Andersen M., et al.: Adjuvant anthracycline in breast cancer. Improved outcome in pre-menopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc. Am. Soc. Clin. Oncol. 18:68a, 1999.
12. Carpenter J.T., Velez-Garcia E., Aron B.S., et al.: Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (adriamycin) and fluorouracil (CAF) vs cyclophosphamide, methotrexate and fluorouracil (CMF) in node positive breast cancer: a Southern Cancer Study Group study. Proc. Am. Soc. Clin. Oncol. 13:66, 1994.
13. Goldhirsch A., Gelber R.D., Price K.N., et al.: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 341:377-381, 1994.
14. Buzdar A.U., McNeese M.D., Hortobagy G.N., et al.: Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer 65:394-99, 1990.
15. Fisher B., Redmond C., Dimitrov N.V., et al.: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor negative tumors. N. Eng. J. Med. 320:473-478, 1989.
16. Singletary S.E., Allred C., Ashley P., et al.: Revision of the American Joint Committee on cancer staging system for breast cancer. J. Clin. Oncol. 20:3628-3636, 2002.
17. Elston C.W., Ellis I.O.: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
18. Hosmer D.W. and Lemeshow S.: Applied survival analysis. Regression modeling of time to event data. NY: Wiley-Interscience publication, 1999.
19. Kleinbaum D.G., Kupper L.L., Muller K.E., Nizam A.: Applied regression analysis and other multivariable model. CA: Duxbury Press, 3rd edition, 1998.
20. Hortobagyi G.N., Buzdar A.U.: Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs 45 (Suppl.):10-19, 1993.
21. Donegan W.L. Local and regional recurrences. In Donegan W.L., Spratt J.S., (eds). Cancer of the breast. PH: W.B. Saunders Company, 4th edition, 1995, 666-81.
22. Kamby C., Sengelov L.: Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. Breast Cancer Res. Treat. 45:181-192, 1997.
23. Ragaz J., Jackson S.M., Le N., et al.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Eng. J. Med. 337:956-962, 1997.
24. Overgaard M., Jensen M., Hansen P.S., et al.: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1648, 1999.
25. Janjan N.A., Murray K.J., Conway P., et al.: Prognosis for breast cancer surgery and radiation therapy compared with mastectomy alone. Cancer 69:2842-2848, 1992.
26. Valagussa P., Bonadonna G., Veronesi U.: Pattern of relapse and survival following radical mastectomy. Cancer 41:1170-1178, 1978.
27. Arriagada R., Rutqvist L.E., Mattson A., et al.: Adequete locoregional treatment for regional treatment for early breast cancer may prevent secondary dissemination. J. Clin. Oncol. 13:2869-2878, 1995.
28. Misset J., di Palma M., Delgado M., et al.: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, Doxorubicin, Fluorouracil, and Vincristine versus cyclophosphamide, Methotrexate, and Fluorouracil: Final report after a 16-year median follow-up duration. J. Clin. Oncol. 14:1136-1145, 1996.
29. Moliterni A., Bonadonna G., Valagussa P., Ferrari L., Zambetti M.: Cyclophosphamide, Methotrexate, and Fluorouracil with and without doxorubicin in the adjuvant treatment of respectable breast carcinomas with one to three positive axillary nodes. J. Clin. Oncol. 9:1124-1130, 1991.
30. Bonadonna G., Veronesi U., Brambilla C., et al.: Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimetres or more. J. Natl. Cancer Inst. 82:1539-1545, 1990.